You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
US FDA approves first generic versions of Lilly's ADHD drug
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
The U.S. Food and Drug Administration approved the first generic versions of Eli Lilly & Co.'s Strattera, a drug for the treatment of attention-deficit hyperactivity disorder in children and adults.
The generic atomoxetine will be marketed in multiple doses by Apotex Inc., Teva Pharmaceutical Industries Ltd.'s Teva Pharmaceuticals USA Inc., Aurobindo Pharma Ltd. and Glenmark Pharmaceuticals Ltd.
Eli Lilly reported Strattera sales of $854.7 million for the full year 2016.